Cogstate is at the forefront of Alzheimer’s research via participation in several key longitudinal public private partnership (PPP) studies such as secondary prevention trials including A4 and DIAN, as well as registries and natural history studies including AIBL, ADNI, BHR, and the APT Webstudy.
Improve Strategic Study Design
Cogstate has the expertise and extensive data sets to advise your team on vital study considerations, help you answer key drug development questions, and reduce risk and uncertainty.
Insights from Key Landmark Studies
Study Design Guidance from Cognitive Science Experts
Utilizing open data sets made available through our involvement in PPPs, Cogstate scientists can advise study teams on endpoint selection, powering decisions, and interpretation of study results supportive of product efficacy, safety, and differentiating claims.
Go/No-Go Decision-Making Frameworks
A paper in Drug Discovery Today—co-authored by two Cogstate scientists—notes how cognitive data can be used for better Go/No-Go decision-making in Alzheimer’s clinical trials and explores how to apply robust decision-making criteria depending on the specific stage of development, mechanism of action, and design of the trial. Read more.